Abstract
Myeloproliferative neoplasms include essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). These 3 diseases have common clinical features, such as a high risk of vascular complications, progression to secondary myelofibrosis, and clonal evolution into the blast phase. Current risk factors of ET and PV, used to predict events, are patient based: age >60 years and a history of thrombosis. Very recently, other parameters, such as leukocyte count and the presence of JAK2 (V617F) mutation, have been reported as potential risk factors. Prognosis in PMF is predicted at diagnosis by a combination of different risk factors, such as advanced age (age >60 years), anemia, leukocytosis (white blood cell count > 25 × 10(9)/L), the presence of blast cells (≥ 1%), and the presence of constitutional symptoms. This model may also predict survival when applied during follow-up.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
